Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
3(38%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
2
25%
Ph phase_3
2
25%

Phase Distribution

2

Early Stage

2

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(3)
Terminated(3)
Other(2)

Detailed Status

Terminated3
Completed3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
50.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (33.3%)
Phase 22 (33.3%)
Phase 32 (33.3%)

Trials by Status

terminated338%
completed338%
unknown225%

Recent Activity

0 active trials
Showing 5 of 8
unknown

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03886506
completedphase_3

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

NCT03006770
terminatedphase_2

Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

NCT04389450
terminatedphase_2

Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19

NCT04614025
completedphase_3

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

NCT03451916
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03886506

Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Unknown
NCT03006770Phase 3

Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Completed
NCT04389450Phase 2

Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

Terminated
NCT04614025Phase 2

Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19

Terminated
NCT03451916Phase 3

Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)

Completed
NCT03746899

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)

Unknown
NCT01795950Phase 1

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Terminated
NCT00951210Phase 1

Safety of Intramuscular Injections (IM) of Allogeneic PLX-PAD Cells for the Treatment of Critical Limb Ischemia (CLI)

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8